Analysis of reporting of adverse drug reactions in a tertiary care hospital: One year survey

Adil Ali Shakur¹, Sukalyan Saha Roy², Lalit Mohan³, Manish Kumar⁴, Hitesh Mishra⁵, Harihar Dikshit⁶, Monesh Likhitkar⁷

¹Senior Resident, ²Assistant Professor, ³Additional Professor, ⁴Associate Professor, ⁵Professor and Head, ⁶Dept. of Pharmacology, ⁷College of Pharmacy, ¹⁵Indira Gandhi Institute of Medical Sciences, Patna, Bihar, ¹⁴IPS Academy, Indore, Madhya Pradesh, India

*Corresponding Author: Monesh Likhitkar
Email: mlkhitkar4@gmail.com

Abstract

Introduction: Adverse drug reactions (ADRs) are inevitable component of drug therapy which negatively affects quality of life, increases physician visits, hospitalizations and even death. It also poses economic burden on health care system.

Aim: To ascertain various ADRs occurring in our hospital; this can generate a notion to inculcate the culture of ADR reporting in view of improving the health safety of patients.

Materials and Methods: A retrospective, record based study, conducted by analyzing ADR forms, reported over a period of 12 months and were further analyzed for demographic details, organ system involved, types of ADRs, suspected drugs, causality, severity, outcome and reporters qualification.

Results: A total of 532 ADR reporting forms were studied in which 563 types of ADRs were seen. Male preponderance (57.1%) was seen with majority of ADRs between 40-59 yrs. of age (33.2%). Gastrointestinal tract (47.24%) was most commonly affected with abdominal pain, diarrhea and nausea. Antibiotics were the most common suspected group of drugs. Majority of ADRs were probable/likely (46.35%) and were of moderate category (56.12%). Most of the patients recovered/resolved (91.35%) from the reaction and majority of reports was from non-health professionals/consumers (53.19%).

Conclusions: Results drawn from this study suggests reinforcing Pharmacovigilance Programme of India as it can help in minimization/prevention of ADRs through early detection. Also, it would be helpful if the system of ADR monitoring is designed in such a way that it encourages health care professionals to report ADRs spontaneously and intensively through a proper communication channel for ensuring patient safety.

Keywords: Adverse drug reaction, Antibiotics, ICSR, IPC, PvPI

Introduction

The evolution of drugs in last decade has given significant benefit to patients but at the same time incidence of Adverse Drug Reaction (ADR) has considerably inflated. ADR as defined by World Health Organization (WHO) is ‘a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease, or for the modification of physiological function’.¹ ADR negatively affects the quality of life, increases physician visits, hospitalizations and even death. It has been observed that drug induced conditions leads to 5% of all hospital admissions and 10–20% of hospitalized patient develops ADRs.² The morbidity and mortality associated with ADRs also poses great economic burden on the health care system of country. In many countries, it ranks among top ten leading cause of morbidity and mortality in both ambulatory as well as in hospitalized patients.³ The risk of ADRs is an intrinsic intimidation to all drug therapy and is influenced by certain factors such as dose, frequency, duration of therapy, drug interactions, genotype and pharmacokinetic profile of special age group patients such as pediatric and geriatric. Due to the soaring prevalence and at times potentially serious repercussion of drug therapy, ADRs may have a dramatic impact in clinical practice and on the health of society.⁴ Therefore, ADR reporting is an important component of monitoring and evaluating drug activity in health care sector.⁵,⁶

Pharmacovigilance an important aspect in this domain aims at making the best use of drugs with the help of high quality data gathered through this reporting system. According to WHO, Pharmacovigilance is defined as ‘the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem’.⁷ WHO initially established its Programme for International Drug Monitoring in 1968. In 1978, Uppsala Monitoring Centre (UMC) a WHO collaborating centre was created in order to support this program. In India, in the year 2010 the Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services under the aegis of Ministry of Health and Family Welfare (MoHFW), launched the nationwide Pharmacovigilance Programme of India (PvPI). Indian Pharmacopoeia Commission (IPC), Ghaziabad under the MoHFW has been functioning as the National Coordination Centre (NCC) for PvPI since April 2011. Under this programme, till date 270 ADR Monitoring Centers (AMCs) had been formed in different medical colleges and hospitals covering the entire country. Owing to indefatigable effort by IPC and AMCs, since April 2011 there has been rapid progress in reporting of ADRs by the healthcare professionals⁸ and the annual database of PvPI for year 2018-19 accounted for 64, 441 reports ⁹ Through these data PvPI regularly recommends the drug regulatory authorities and suggests the healthcare professionals for improving the safe use of drugs. However, despite the effort of national and international authorities, under-reporting is still quite common, i.e., only 1% as compared to 5% in
other countries. There is a considerable need to create and enhance awareness in community and healthcare professionals about the importance of monitoring drug outcomes. Awareness regarding the detection, management, prevention, and reporting of ADR is utmost important for improving patient care and to reduce the cost. This study is thus aimed to strengthen the ADR database through retrospective analysis and compilation of the pattern of ADRs and suspected drugs reported to our AMC, which can generate a notion among clinicians of this region to inculcate the culture of ADR reporting in view of improving the health safety of patients. Moreover, the regional data generated from this study can also help in planning the institute/ state health policy.

Materials and Methods
This was a retrospective, record based study and was commenced after obtaining due approval from the Institutional Ethics Committee (1121/IEC/2019). This study was conducted by analyzing the suspected ADR forms which were reported over a period of 12 months (August 2018 to July 2019) from various clinical departments of our institute to its ADR Monitoring Centre i.e., Department of Pharmacology. A total of 532 reported ADRs were evaluated for mandatory parameters including patient’s detail, type of ADR, drugs causing ADR, etc. as per Standard Operating Procedure (SOP) of IPC, Ghaziabad and was further studied retrospectively with the help of Individual Case Safety Reports (ICSRs) and other additional documents such as prescriptions and investigation reports (where necessary). After analysis, results were categorized as follows:

1. Demographic detail of patients
2. Organ system involved
3. Types of ADRs
4. Suspected drugs causing ADRs
5. Causality assessment of ADRs
6. Severity assessment of ADRs
7. Outcome of ADRs
8. Reporters qualification

Results
During one year, i.e., from August 2018 to July 2019 a total of 532 ADR reporting forms were collected in which 563 types of ADRs were seen. The gender distribution showed male preponderance as compared to females. The majority of patients who suffered from ADRs were between 40-59 yrs. of age. (Table 1)

Table 1: Demographic details

| Gender distribution | Number of patients (Total=532) | Percentage of patients |
|---------------------|---------------------------------|------------------------|
| Male                | 304                             | 57.1                   |
| Female              | 228                             | 42.8                   |

| Age distribution | Number of patients (Total=532) | Percentage of patients |
|------------------|---------------------------------|------------------------|
| 0-19             | 41                              | 7.7                    |
| 20-39            | 174                             | 32.7                   |
| 40-59            | 177                             | 33.2                   |
| >60              | 140                             | 26.3                   |

On analysis of the organ systems, gastrointestinal tract (GIT) was most commonly affected followed by central nervous system (CNS), skin, generalized, cardiovascular system (CVS), respiratory system, and hematological system. From the respective systems the most common types of ADRs were abdominal pain, diarrhea, nausea, headache, dizziness, insomnia, rash, pruritus, fatigue myalgia, palpation, cough and anemia. (Table 2)

Table 2: Organ System and associated ADRs

| Organ systems involved | Types of ADRs                                                                 | n (%)                     |
|------------------------|------------------------------------------------------------------------------|---------------------------|
| Gastrointestinal tract| Abdominal pain (67), Diarrhoea (46), Nausea (46), Dry mouth (41), Constipation (26), Vomiting (16), Dyspepsia (07), Indigestion (04), Anorexia (04), Heartburn (03), Dysguesia (03), Stomatitis (02), Bloating (01) | 266(47.24%)               |
| Central nervous system| Headache (42), Dizziness (27), Insomnia (20), Drowsiness (17), Sleepiness (07), Tremor (05), Restlessness (04), Nervousness (02), Vertigo (02), Sweating (02), Mood swings (01) | 129(22.91%)               |
| Skin                  | Rash (41), Pruritus (27), Angioedema (02), Alopecia (01)                      | 71(12.61%)                |
On total 477 drugs were suspected of causing 563 types of ADRs from which 124 drugs were antibiotics and were the most common group of drug associated with ADRs, followed by analgesics, hormones & related drugs, antidepressants, proton pump inhibitors, antihistaminics, miscellaneous drugs, antipsychotics, anticonvulsants, antihypertensives, antiepileptics, diuretics, antiangiobics, antituberculars, antianxieties, anticancers, antihelminetics, beta blockers, hypolipidaemics, bronchodilators, antivertigo drugs, antivirals, 5α reductase inhibitors, muscle relaxants, antifibrinolitics, antiplatelets and antigout. From the respective groups, most offending drugs were Amoxicillin+clarulanic acid, Paracetamol, Prednisolone, Escalopram, Esomeprazole, Levocetrizine, Pregabalin+Nortriptylline, Olanzapine, Levetiracetam, Amlodipine, Onadsetron, Spiranolactone+Torasemide, Metronidazole, Bedaquine, Clonazepam, Cisplatin, Alendazole, Metoprolol, Rozuvastatin, Doxophylline, Betahistine, Tenofovir, Dutasteride, Tizanidine, Tranexamic acid, Clopidogrel and Febuxostat (Table 3)

**Table 3: Suspected drugs causing ADRs**

| Drug Class                      | Suspected Drugs                                                                 |
|---------------------------------|---------------------------------------------------------------------------------|
| Antibiotics (n=124)             | Amoxicillin+Clavulanic acid (17), Levofloxac(16), Ceftriaxone (14), Azithromycin (11), Cefixime (11), Cefpodoxime (07), Cefuroxime (07), Cefoperazone+ Sulbactam (06), Ofloxac (06), Piperacillin+Tazobactam (04), Clarithromycin (04), Ciprofloxacin (03), Amikacin (03), Rifaxim (03), Doxycclylone (03), Tetracycline (02), Moxifloxacin (02), Clindamycin (01), Linezolid (01), Faropenem (01), Cefazidine (01), Moxifloxacin (01) |
| Analgesics (n=54)               | Paracetamol (14), Tramadol (10), Dicyclomine+Mephanemic acid (08), Diclofenac (07), Acceleofenac (06), Piroxicam (04), Eticoricoxib (02), Lornoxicam (01), Naproxen (01), Ibuprofen (01) |
| Hormones & related drugs (n=39) | Prednisolone (14), Thyroxine (08), Hydrocortisone (03), Deflazacort (02), Teneligliptin (02), Dexamethasone (02), Metformin (02), Loteprednol (01), Danazol (01), Medroxyprogesterone (01), Budesonide (01), Glibencamide (01), Glymepride (01) |
| Antidepressants (n=25)          | Escitalopram (10), Amitriptilin (06), Sertraline (03), Mirtazapine (03), Paroxetine (02), Duloxetine (01) |
| Proton Pump Inhibitors (n=24)   | Esomeprazole (14), Rabeprazole (10) |
| Antihistaminics (n=21)          | Levocetrizine (07), Fexofenadine (06), Montelukast (05), Hydroxyzine (02), Cetirizine (01) |
| Miscellaneous drugs (n=19)      | Pregabalin+Nortriptylline (05), Naproxem+Dopmeridone (03), Chlorziazepoxide+Clidinium (03), Calcium citrate (02), Benfortiamine (02), Pantoprazole+Flunarizine (02), Ferrous fumarate (01), Methylcobalamin (01) |
| Antipsychotics (n=18)           | Olanzapine (09), Aripiprazole (04), Quetiapine (02), Fluphenixol (01), Palperidone (01), Clozapine (01) |
| Anticonvulsants (n=18)          | Levetiracetam (11), Phenytoin (03), Lacosamide (01), Carbamazepine (01), Valproic acid (01), Topiramate (01) |
| Antihypertensives (n=18)        | Amlodipine (8), Telmisartan (02), Cilnidipine (02), Nimodipine (02), Olmesartan (01), Carvedilol (01), Losartan (01), Ramipril (01) |
| Antiemetics (n=15)              | Ondansetron (08), Domperidone (06), Granisetron (01) |
| Diuretics (n=13)                | Spironolactone+Torasemide (06), Furosemide (05), Furosemide+Lasilactone (02) |
| Antiamoebic (n=12)              | Metronidazole (08), Ornidazole (04) |
| Antituberculars (n=11)          | Bedaquine (09), Rifampicin (01), Pyrazamidine (01) |
| Antianxiety (n=10)              | Clonazepam (07), Etizolam (02), Lorazepam (01) |
| Anticancer (n=10)               | Cisplatin (04), Rituximab (02), Gemcitabine (02), Asparaginase (01), Methotrexate (01) |
| Antihelmintics (n=07)           | Albendazole (05), Albendazole+Ivermectin (02) |
| Beta blockers (n=06)            | Metoprolol (03), Labetalol (01), Timolol (01), Propranolol (01) |
| Hypolipidaemics (n=06)          | Rozuvastatin (06) |
| Bronchodilators (n=05)          | Doxophylline (02), Salbutamol (01), Aminophylline (01), Formoterol (01) |
| Antivertigo (n=04)              | Betahistine (03), Cinnarizine+Dimenhydrinate (01) |

*IP International Journal of Comprehensive and Advanced Pharmacology, January-March, 2020*
The analysis of causality assessment showed that the maximum ADRs reported were probable/likely (46.35%). This was followed by possible (41.03%), unlikely (11.54%) and certain (1.06%). Conditional/Unclassified and Unassessable/Unclassifiable were found to be nil (Fig. 1).

Fig. 1: Causality of reported ADRs

On analysis of severity assessment, it was found 56.12% ADRs belonged to moderate category. 43.33% ADRs belonged to minor category and 0.53% ADRs were of severe category (Fig. 2).

Fig. 2: Severity assessment of ADRs

The outcome of these ADRs was that most of the patients i.e., 91.35% recovered/resolved, 7.7% were recovering/resolving. The outcome of 0.75% cases was unknown and 0.18% case did not recovered/ongoing at the time of report (Fig. 3).

Fig. 3: Outcome of ADRs

The reporter qualification showed that 53.19% reports were from non-health professionals/consumers, 39.66% reports were from other health professionals and 7.14% were from physicians. (Fig. 4)

Fig. 4: Reporters qualification

Discussion

In this study, males were more affected with ADRs than females which are in concordance with several other studies. However, some studies showed female preponderance which is in contrast to our study. Thereby concluding that influence of gender is just an incidental finding and it does not affect number of ADRs reported. The age group most commonly affected was 40-59 years, which may be attributed to the more number of concomitant drugs being taken by this age group in our centre, this was similar in other studies also.

The most common organ system affected with ADR was GIT and is consistent with some other studies but it differs from reports of Fredy et al where skin manifestations had the highest rate, which was third highest in our study.
The most common suspected drug responsible for ADRs were antibiotics which may be due to the reason that antibiotics were the most commonly prescribed either for prophylactic or curative therapy. The results were consistent with previous studies. Analgesics were reported to be the second most common group of drug causing ADRs which in some other studies had been reported to be the most common group of suspected drugs.

According to WHO-UMC causality assessment criteria majority of the ADRs were of probable/likely category with the suspected drug, followed by possible, unlikely and certain. These results were similar to some studies but different from the results observed in them. According to modified Hartwig and Siegel severity scale major part of the ADRs belonged to moderate category, followed by mild and severe category. These patterns of ADRs were consistent with other studies. In outcome of the reactions, most of the patients have shown recovery after the withdrawal of offending drug and/or with treatment of ADRs, followed by recovering/resolving, unknown outcomes and only one severe case at the time of respective reports.

The present study showed that major reporting was done by non-health professionals/consumers who were followed by other health professionals and physicians accounted for least number of reports. There are various probable reasons identified for underreporting which in part happens due to the voluntary notification system mainly. Other reasons could be attributed to lack of attitude, time constraint, work overload of healthcare professionals, having misbelief that adverse events that are already known and which have a causal relationship with the offending drug are not to be reported, hesitancy of health professionals to report because they fear litigation and think reporting might go against them. Similar trend and rational has also been stated by other studies. However, all the health care professionals extended their support in validating the ADRs.

This study has quite limitations, such as; due to the nature of our study, sensitization of health care professional regarding ADR reporting cannot be done. Due to lack of communication and consequently scanty documentation at the time of reporting we were not able to draw results in parameters such as preventability assessment, action taken due to ADR, management of ADRs, concomitant medications and relevant medical/medication history. In future, fluent communication between AMCs and healthcare professional/ consumers could help in documenting more relevant information which could mitigate these drawbacks.

Conclusion
The present study exhibits an exemplary profile of the ADRs which strongly suggests that it is need of the hour to reinforce the existing Government’s Pharmacovigilance Programme of India as it can help in minimization or prevention of ADRs through early detection and effective communication, which can ultimately help each patient to receive optimum therapy. Knowing the importance of this programme, our AMC has been working tirelessly since its recognition by IPC, i.e., December 2012 and has reported 1999 cases to IPC till December 2019. In past various sensitization activities had been conducted/organized by our AMC in form of seminar/workshop for health care professionals and street-shows for consumers/non-health professionals. In addition to this, toll-free number of IPC and contact number of our AMC has been incorporated in the OPD prescription of our institute for better and easy communication which resulted in considerable reporting by non-health professionals/consumers. Much has been done but more is to be done. Hence, it would be more helpful if the system of ADR monitoring is designed in such a way that it encourages clinicians and other health care professionals to report ADRs spontaneously and intensively through a proper communication channel for ensuring patient safety.

Source of funding
None.

Conflict of interest
None.

References
1. International drug monitoring; the role of the hospital [Internet]. Geneva: World Health Organization, technical report series no. 425;1969 [citied 1 February 2020]. Available from: https://apps.who.int/iris/handle/10665/2
2. Ratan JL, Mangala L, Sukirti D. A study on adverse drug reactions in a tertiary care hospital of northeast India. Alex J Med 2017;53:151-6.
3. Shamma N, Dilip C, Ajmal M, Linu PM, Shino C, Jafer CP. A prospective study on Adverse Drug Reactions of antibiotics in a tertiary care hospital. Saudi Pharm J 2013;12:30-3
4. Sultana J, Cutrono P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmaco Pharmaeother 2013; 4:73-7.
5. Lobo MG, Pinheiro SM, Castro JG, Momente VG, Pranchevicius MC. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in northern Brazil. BMC Pharm Toxicol 2013;14:5
6. Adithan C, The national pharmacovigilance program. Indian J Pharm 2005; 37:347
7. Pharmacovigilance [Internet]. World Health Organization. [citied 1 February 2020]. Available from: https://www.who.int/medicines/areas/quality_safety/safety_efficiency/pharmvigis/en/
8. PVP reaches out to rural masses [Internet]. Ghaziabad: Indian Pharmacopoeia Commission; 2017 [citied 1 February 2020]. Available from: https://ipc.gov.in/Pvp/Newsletter3/newsletter3.html
9. Suspected adverse drug reaction reporting form [Internet]. Ghaziabad: Indian Pharmacopoeia Commission; [citied 1 February 2020]. Available from: https://ipc.gov.in/mandates/pvpi/pvpi-updates.html
10. UMC | VigiFlow [Internet]. Who-umc.org. [citied 1 February 2020]. Available from: https://www.who-umc.org/global-pharmacovigilance/vigiflow/
11. Lihite RJ, Lahkar M. An update on the Pharmacovigilance Programme of India. Front Pharmacol 2015; 6:194
12. Kalaiselvan V, Thota P, Singh GN. Pharmacovigilance programme of India: recent developments and future perspectives. India J Pharmcol 2016; 48:624–8.

13. Pharmacovigilance Programme of India (PvPI) Updates: Performance Report 2018-19 [Internet]; Ghaziabad: Indian Pharmacopoeia Commission; 2019 [cited 2 February 2020]. Available from: https://ipc.gov.in/mandates/pvpi/pvpi-updates/8-category-en/646-annual-performance-report

14. Upadhyaya HB, Vora MB, Nagar JG, Patel PB. Knowledge, attitude and practices toward pharmacovigilance and adverse drug reactions in postgraduate students of tertiary care hospital in Gujarat. J Adv Pharm Technol Res 2015; 6:29–34.

15. Hennessy S, Strom B. PDUFA Reauthorization — Drug Safety’s Golden Moment of Opportunity. Engl J Med 2007;356:1703-4.

16. Tandon VR, Sharma S, Khajuria V, Mahajan V, Gillani Z. Adverse drug reactions profile of antimicrobials: A 3-year experience, from a tertiary care teaching hospital of India. Indian J Med Microbiol 2015; 33:393-400.

17. Dutta SB, Beg MA, Bawa S, Anjoom M, Varma A, Singh NK. A retrospective analysis of adverse drug reactions in a tertiary care teaching hospital at Dehradun, Uttarakhand. Int J Basic Clin Pharmacol 2015; 4:121-4.

18. Shamna M, Dilip C, Ajmal M, Linu Mohan P, Shini C, Jafer CP, et al. prospective study on adverse drug reactions of antibiotics in a tertiary care hospital. Saudi J Pharm J 2014; 22:303-8.

19. Miller MA. Gender-based differences in the toxicity of pharmaceuticals - the food and drug Administration’s perspective. Int J Toxicol 2001; 20:149-52.

20. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian hospital - their severity and cost involved. Pharmacoepidemiol Drug Saf 2003;12:687-92.

21. Kharp P, Mittal N, Gupta MC. An evaluation of adverse drug reactions monitoring at a pharmacovigilance unit under pharmacovigilance programme of India in a tertiary care hospital of Haryana. Int J Basic Clin Pharmacol 2015:4:556-60.

22. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ et al. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharmacol 2007;7:8.

23. Suh DC, Woodall BC, Shin SK, Shin SK, Hermes-De Santis ER. Clinical and economic impact of adverse drug reactions in hospitalized patients. Ann Pharmacother 2000; 34:1373-8.

24. Venkatasubbaiah M, Dwarkanadh Reddy P, Satyanarayana S. Analysis and reporting of adverse drug reactions at a tertiary care teaching hospital. Alexandria J Med 2018;54:597-603.

25. Freedy IC, Chandrashekhar S, Srinivasan R. Retrospective analysis of reported adverse drug reactions. Indo Am J Pharm Sci 2015; 3:8.

26. Sneha G, Sowmya N, Prem KG. An observational prospective study on prevalence and monitoring of adverse drug reactions in tertiary care teaching hospital. BJPR 2016;11:1–9.

27. Kiran R, Divya S, Prathiba N, Bhanu P. Monitoring and analysis of drug reactions in a private tertiary care teaching hospital. Asian J Pharm Clin Res 2018; 8:335-7.

28. Sen M, Singh A, Misra M. Retrospective analysis of adverse drug reactions reported at ADR monitoring centre under PvPI in a tertiary care hospital. Int J Basic Clin Pharmacol 2018;7:303-8.

29. Patel RM, Marfatia YS. Clinical study of cutaneous drug reaction in 200 patients. Indian J Dermatol Venereol Leprol 2008;74:430.

30. Naranjo CA, Busto U, Sellars EM, Sandor P, Ruiz I, Roberts EA. A method for estimating the probability of adverse drug reactions. Clin Pharm Ther 1981; 30:239-45.

31. Saxena K, Tailor C, Mehta C, Gajera P, Srivastava SK. A retrospective analysis of adverse drug reaction reported in a tertiary care hospital. Int J Basic Clin Pharmacol 2017; 6:1146-50.

32. Priyadharsini R, Surendiran A, Adithan C, Sreenivasan S, Sahoo FK. A study of adverse drug reactions in pediatric patients. J Pharmacol Pharmacother 2011; 2:277-80.

33. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992; 49:2229-32.

34. Shareef SM, Naidu CDM, Raikar SR, Rao YV, Devika U. Development, implementation and analysis of adverse drug reaction monitoring system in a rural tertiary care teaching hospital in Narketpally Telangana. Int J Basic Clin Pharmacol 2015;4:757-60.

35. Vijayakumar TM, Dhanaraju MD. Description of adverse drug reactions in a multi-speciality teaching hospital. Int J Integr Med 2013;1:1-6.

How to cite: Shakur AA, Roy SS, Mohan L, Kumar M, Mishra H, Dikshit H, Likhitkar M. Analysis of reporting of adverse drug reactions in a tertiary care hospital: One year survey. IP Int J Comprehensive Adv Pharmacol 2019:5(1):25-30.